Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Context Therapeutics Inc.CNTX · Entity 7406 | Director · Chief Executive Officer | February 19, 2026 | February 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Context Therapeutics Inc.
Report date February 19, 2026 · Filed February 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.32 · Expires 2036-02-18 | Direct | 815,000 |
Reported balance
After 2026-02-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-19 · Grant · Acquired 815,000 · Balance 815,000 F1: The option vests and becomes exercisable over a four-year period. Twenty-five percent (25%) of the option vests and becomes exercisable on February 19, 2027, and the balance vests in equal monthly installments over the remaining three years of the four-year period, subject to continued service with the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests and becomes exercisable over a four-year period. Twenty-five percent (25%) of the option vests and becomes exercisable on February 19, 2027, and the balance vests in equal monthly installments over the remaining three years of the four-year period, subject to continued service with the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 19, 2026 Filed Feb 23, 2026 16:13 UTC | Context Therapeutics Inc. CNTX · Entity 7406 | GrantStock Option (right to buy) · Derivative | 815,000 | $0.00 Strike: $2.32 | $0.00 |
DisclosureSEC source: 0001628280-26-010616 · wk-form4_1771881235.xml · derivative · entry 1 Lehr Martin A. · CIK 0001861989 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 815,000 Underlying: Common Stock · 815,000 shares Expires 2036-02-18 F1 · derivative.exercise_date: The option vests and becomes exercisable over a four-year period. Twenty-five percent (25%) of the option vests and becomes exercisable on February 19, 2027, and the balance vests in equal monthly installments over the remaining three years of the four-year period, subject to continued service with the Issuer. Read SEC document |
| June 09, 2025 Filed Jun 10, 2025 17:26 UTC | Context Therapeutics Inc. CNTX · Entity 7406 | PurchaseCommon Stock | 100,000 | $0.70 | $70,080.00 |
DisclosureSEC source: 0001842952-25-000064 · wk-form4_1749590774.xml · nonDerivative · entry 1 Lehr Martin A. · CIK 0001861989 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Martin Lehr 2000 Trust Disclosed balance after: 920,190 F1 · price: The price reported above is a weighted average price. These shares were acquired in several transactions at prices ranging from $0.6682 - $0.75. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 13, 2025 Filed Feb 14, 2025 16:06 UTC | Context Therapeutics Inc. CNTX · Entity 7406 | GrantStock Option (right to buy) · Derivative | 802,700 | $0.00 Strike: $0.81 | $0.00 |
DisclosureSEC source: 0001842952-25-000019 · wk-form4_1739567178.xml · derivative · entry 1 Lehr Martin A. · CIK 0001861989 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 802,700 Underlying: Common Stock · 802,700 shares Expires 2035-02-12 F1 · derivative.exercise_date: The option vests and becomes exercisable over a four-year period. Twenty-five percent (25%) of the option vests and becomes exercisable on February 13, 2026, and the balance vests in equal monthly installments over the remaining three years of the four-year period, subject to continued service with the Issuer. Read SEC document |
| March 21, 2024 Filed Mar 22, 2024 08:01 UTC | Context Therapeutics Inc. CNTX · Entity 7406 | GrantStock Option (right to buy) · Derivative | 291,402 | $0.00 Strike: $1.07 | $0.00 |
DisclosureSEC source: 0001842952-24-000017 · wk-form4_1711108859.xml · derivative · entry 1 Lehr Martin A. · CIK 0001861989 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 291,402 Underlying: Common Stock · 291,402 shares Expires 2034-03-20 F1 · derivative.exercise_date: The option vests and becomes exercisable over a four-year period. Twenty-five percent (25%) of the option vests and becomes exercisable on March 21, 2025, and the balance vests in equal monthly installments over the remaining three years of the four-year period, subject to continued service with the Issuer. Read SEC document |
| February 21, 2023 Filed Feb 21, 2023 20:05 UTC | Context Therapeutics Inc. CNTX · Entity 7406 | PurchaseCommon Stock | 5,823 | $0.84 | $4,900.05 |
DisclosureSEC source: 0001842952-23-000030 · wf-form4_167702790361209.xml · nonDerivative · entry 1 Lehr Martin A. · CIK 0001861989 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,701 F1 · kind: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 15, 2022. F2 · price: The price reported above is a weighted average price. These shares were acquired in several transactions at prices ranging from $0.8154 - $0.8470. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 13, 2023 Filed Feb 13, 2023 16:03 UTC | Context Therapeutics Inc. CNTX · Entity 7406 | PurchaseCommon Stock | 5,606 | $0.87 | $4,900.77 |
DisclosureSEC source: 0001842952-23-000020 · wf-form4_167632218722654.xml · nonDerivative · entry 1 Lehr Martin A. · CIK 0001861989 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,878 F1 · kind: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 15, 2022. F2 · price: The price reported above is a weighted average price. These shares were acquired in several transactions at prices ranging from $0.8563 - $0.8938. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 13, 2023 Filed Feb 14, 2023 17:04 UTC | Context Therapeutics Inc. CNTX · Entity 7406 | GrantStock Option (right to buy) · Derivative | 287,544 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001842952-23-000027 · wf-form4_167641224437732.xml · derivative · entry 1 Lehr Martin A. · CIK 0001861989 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 287,544 Underlying: Common Stock · 287,544 shares Expires 2033-02-12 F1 · derivative.exercise_date: The option vests and becomes exercisable over a four-year period. Twenty-five percent (25%) of the option vests and becomes exercisable on February 13, 2024, and the balance vests in equal monthly installments over the remaining three years of the four-year period, subject to continued service with the Issuer. Read SEC document |
| February 06, 2023 Filed Feb 6, 2023 16:03 UTC | Context Therapeutics Inc. CNTX · Entity 7406 | PurchaseCommon Stock | 5,040 | $0.97 | $4,900.39 |
DisclosureSEC source: 0001842952-23-000017 · wf-form4_167571737374433.xml · nonDerivative · entry 1 Lehr Martin A. · CIK 0001861989 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,272 F1 · kind: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 15, 2022. F2 · price: The price reported above is a weighted average price. These shares were acquired in several transactions at prices ranging from $0.9449 - $1.00. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 30, 2023 Filed Jan 30, 2023 16:03 UTC | Context Therapeutics Inc. CNTX · Entity 7406 | PurchaseCommon Stock | 7,027 | $0.70 | $4,900.63 |
DisclosureSEC source: 0001842952-23-000012 · wf-form4_167511259579472.xml · nonDerivative · entry 1 Lehr Martin A. · CIK 0001861989 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,232 F1 · kind: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 15, 2022. F2 · price: The price reported above is a weighted average price. These shares were acquired in several transactions at prices ranging from $0.682 - $0.70. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 23, 2023 Filed Jan 23, 2023 17:03 UTC | Context Therapeutics Inc. CNTX · Entity 7406 | PurchaseCommon Stock | 6,839 | $0.72 | $4,900.83 |
DisclosureSEC source: 0001842952-23-000008 · wf-form4_167451138827052.xml · nonDerivative · entry 1 Lehr Martin A. · CIK 0001861989 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,205 F1 · kind: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 15, 2022. F2 · price: The price reported above is a weighted average price. These shares were acquired in several transactions at prices ranging from $0.7052 - $0.7251. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 17, 2023 Filed Jan 18, 2023 16:04 UTC | Context Therapeutics Inc. CNTX · Entity 7406 | PurchaseCommon Stock | 6,783 | $0.74 | $4,995.00 |
DisclosureSEC source: 0001842952-23-000006 · wf-form4_167407584583579.xml · nonDerivative · entry 1 Lehr Martin A. · CIK 0001861989 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,366 F1 · kind: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 15, 2022. F2 · price: The price reported above is a weighted average purchase price. These shares were acquired in several transactions at prices ranging from $0.7298 - $0.74. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 16, 2022 Filed Dec 19, 2022 16:11 UTC | Context Therapeutics Inc. CNTX · Entity 7406 | PurchaseCommon Stock | 20,000 | $0.74 | $14,796.00 |
DisclosureSEC source: 0001842952-22-000112 · wf-form4_167148401293928.xml · nonDerivative · entry 1 Lehr Martin A. · CIK 0001861989 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,583 Read SEC document |
| August 19, 2022 Filed Aug 22, 2022 16:04 UTC | Context Therapeutics Inc. CNTX · Entity 7406 | PurchaseCommon Stock | 13,000 | $1.85 | $24,064.30 |
DisclosureSEC source: 0001842952-22-000081 · wf-form4_166119862135485.xml · nonDerivative · entry 1 Lehr Martin A. · CIK 0001861989 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,583 Read SEC document |
| February 25, 2022 Filed Feb 25, 2022 16:38 UTC | Context Therapeutics Inc. CNTX · Entity 7406 | GrantStock Option (right to buy) · Derivative | 254,300 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001842952-22-000018 · wf-form4_164582507420064.xml · derivative · entry 1 Lehr Martin A. · CIK 0001861989 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,300 Underlying: Common Stock · 254,300 shares Expires 2032-02-24 F1 · derivative.exercise_date: The option vests and becomes exercisable over a four-year period. Twenty-five percent (25%) of the option vests and becomes exercisable on February 25, 2023, and the balance vests in equal monthly installments (rounded down to the nearest whole share) over the remaining three years of the four-year period, subject to continued service with the Issuer. Read SEC document |
| December 16, 2021 Filed Dec 20, 2021 16:02 UTC | Context Therapeutics Inc. CNTX · Entity 7406 | PurchaseCommon Stock | 13,000 | $3.22 | $41,849.60 |
DisclosureSEC source: 0001842952-21-000029 · wf-form4_164003409890044.xml · nonDerivative · entry 1 Lehr Martin A. · CIK 0001861989 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Martin Lehr 2000 Trust Disclosed balance after: 820,190 Read SEC document |
| October 22, 2021 Filed Oct 25, 2021 17:30 UTC | Context Therapeutics Inc. CNTX · Entity 7406 | ConversionSeries Seed Preferred Stock · Derivative | 586,476 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-21-009609 · edgar.xml · derivative · entry 7 Lehr Martin A. · CIK 0001861989 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Martin Lehr 2000 Trust Disclosed balance after: 0 Underlying: Common Stock · 586,476 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of Series Seed Preferred Stock had no expiration date and automatically converted into one share of Common Stock upon the closing of the Issuer's initial public offering. F3 · price: Each share of Series Seed Preferred Stock had no expiration date and automatically converted into one share of Common Stock upon the closing of the Issuer's initial public offering. F2 · derivative.exercise_date: Fully vested. F3 · derivative.expiration_date: Each share of Series Seed Preferred Stock had no expiration date and automatically converted into one share of Common Stock upon the closing of the Issuer's initial public offering. Read SEC document |
| October 22, 2021 Filed Oct 25, 2021 17:30 UTC | Context Therapeutics Inc. CNTX · Entity 7406 | ConversionSeries A Preferred Stock · Derivative | 210,722 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-21-009609 · edgar.xml · derivative · entry 6 Lehr Martin A. · CIK 0001861989 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Martin Lehr 2000 Trust Disclosed balance after: 0 Underlying: Common Stock · 210,722 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock had no expiration date and automatically converted into one share of Common Stock upon the closing of the Issuer's initial public offering. F1 · price: Each share of Series A Preferred Stock had no expiration date and automatically converted into one share of Common Stock upon the closing of the Issuer's initial public offering. F2 · derivative.exercise_date: Fully vested. F1 · derivative.expiration_date: Each share of Series A Preferred Stock had no expiration date and automatically converted into one share of Common Stock upon the closing of the Issuer's initial public offering. Read SEC document |
| October 22, 2021 Filed Oct 25, 2021 17:30 UTC | Context Therapeutics Inc. CNTX · Entity 7406 | OtherWarrant (right to buy) · Derivative | 52,680 | $0.00 Strike: $7.14 | $0.00 |
DisclosureSEC source: 0001179110-21-009609 · edgar.xml · derivative · entry 5 Lehr Martin A. · CIK 0001861989 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Martin Lehr 2000 Trust Disclosed balance after: 0 Underlying: Common Stock · 52,680 shares Expires 2030-12-20 Read SEC document |
| October 22, 2021 Filed Oct 25, 2021 17:30 UTC | Context Therapeutics Inc. CNTX · Entity 7406 | ConversionCommon Stock | 586,476 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-21-009609 · edgar.xml · nonDerivative · entry 4 Lehr Martin A. · CIK 0001861989 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Martin Lehr 2000 Trust Disclosed balance after: 849,878 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each share of Series Seed Preferred Stock had no expiration date and automatically converted into one share of Common Stock upon the closing of the Issuer's initial public offering. Read SEC document |
| October 22, 2021 Filed Oct 25, 2021 17:30 UTC | Context Therapeutics Inc. CNTX · Entity 7406 | ConversionCommon Stock | 210,722 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-21-009609 · edgar.xml · nonDerivative · entry 3 Lehr Martin A. · CIK 0001861989 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Martin Lehr 2000 Trust Disclosed balance after: 263,402 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock had no expiration date and automatically converted into one share of Common Stock upon the closing of the Issuer's initial public offering. Read SEC document |
| October 22, 2021 Filed Oct 25, 2021 17:30 UTC | Context Therapeutics Inc. CNTX · Entity 7406 | OtherCommon Stock | 52,680 | $7.14 | $376,135.20 |
DisclosureSEC source: 0001179110-21-009609 · edgar.xml · nonDerivative · entry 2 Lehr Martin A. · CIK 0001861989 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Martin Lehr 2000 Trust Disclosed balance after: 52,680 Read SEC document |
| October 22, 2021 Filed Oct 25, 2021 17:30 UTC | Context Therapeutics Inc. CNTX · Entity 7406 | PurchaseCommon Stock | 10,000 | $5.00 | $50,000.00 |
DisclosureSEC source: 0001179110-21-009609 · edgar.xml · nonDerivative · entry 1 Lehr Martin A. · CIK 0001861989 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,583 Read SEC document |
| October 22, 2021 Filed Dec 17, 2021 16:18 UTC Amendment | Context Therapeutics Inc. CNTX · Entity 7406 | ConversionSeries Seed Preferred Stock · Derivative | 586,475 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001842952-21-000027 · wf-form4a_163977590040895.xml · derivative · entry 8 Lehr Martin A. · CIK 0001861989 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Martin Lehr 2000 Trust Disclosed balance after: 1 Underlying: Common Stock · 586,475 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of Series Seed Preferred Stock had no expiration date and automatically converted into one share of Common Stock upon the closing of the Issuer's initial public offering. F2 · price: Each share of Series Seed Preferred Stock had no expiration date and automatically converted into one share of Common Stock upon the closing of the Issuer's initial public offering. F3 · derivative.exercise_date: Fully vested. F2 · derivative.expiration_date: Each share of Series Seed Preferred Stock had no expiration date and automatically converted into one share of Common Stock upon the closing of the Issuer's initial public offering. Read SEC document |
| October 22, 2021 Filed Dec 17, 2021 16:18 UTC Amendment | Context Therapeutics Inc. CNTX · Entity 7406 | ConversionSeries A Preferred Stock · Derivative | 210,715 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001842952-21-000027 · wf-form4a_163977590040895.xml · derivative · entry 7 Lehr Martin A. · CIK 0001861989 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Martin Lehr 2000 Trust Disclosed balance after: 7 Underlying: Common Stock · 210,715 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock had no expiration date and automatically converted into one share of Common Stock upon the closing of the Issuer's initial public offering. F1 · price: Each share of Series A Preferred Stock had no expiration date and automatically converted into one share of Common Stock upon the closing of the Issuer's initial public offering. F3 · derivative.exercise_date: Fully vested. F1 · derivative.expiration_date: Each share of Series A Preferred Stock had no expiration date and automatically converted into one share of Common Stock upon the closing of the Issuer's initial public offering. Read SEC document |
| October 22, 2021 Filed Dec 17, 2021 16:18 UTC Amendment | Context Therapeutics Inc. CNTX · Entity 7406 | OtherWarrant (right to buy) · Derivative | 52,680 | $0.00 Strike: $7.14 | $0.00 |
DisclosureSEC source: 0001842952-21-000027 · wf-form4a_163977590040895.xml · derivative · entry 6 Lehr Martin A. · CIK 0001861989 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Martin Lehr 2000 Trust Disclosed balance after: 0 Underlying: Common Stock · 52,680 shares Expires 2030-12-20 Read SEC document |
| October 22, 2021 Filed Dec 17, 2021 16:18 UTC Amendment | Context Therapeutics Inc. CNTX · Entity 7406 | PurchaseCommon Stock | 10,000 | $5.00 | $50,000.00 |
DisclosureSEC source: 0001842952-21-000027 · wf-form4a_163977590040895.xml · nonDerivative · entry 5 Lehr Martin A. · CIK 0001861989 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Martin Lehr 2000 Trust Disclosed balance after: 807,190 Read SEC document |
| October 22, 2021 Filed Dec 17, 2021 16:18 UTC Amendment | Context Therapeutics Inc. CNTX · Entity 7406 | ConversionCommon Stock | 586,475 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001842952-21-000027 · wf-form4a_163977590040895.xml · nonDerivative · entry 4 Lehr Martin A. · CIK 0001861989 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Martin Lehr 2000 Trust Disclosed balance after: 797,190 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each share of Series Seed Preferred Stock had no expiration date and automatically converted into one share of Common Stock upon the closing of the Issuer's initial public offering. Read SEC document |
| October 22, 2021 Filed Dec 17, 2021 16:18 UTC Amendment | Context Therapeutics Inc. CNTX · Entity 7406 | ConversionCommon Stock | 210,715 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001842952-21-000027 · wf-form4a_163977590040895.xml · nonDerivative · entry 3 Lehr Martin A. · CIK 0001861989 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Martin Lehr 2000 Trust Disclosed balance after: 210,715 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock had no expiration date and automatically converted into one share of Common Stock upon the closing of the Issuer's initial public offering. Read SEC document |
| October 22, 2021 Filed Dec 17, 2021 16:18 UTC Amendment | Context Therapeutics Inc. CNTX · Entity 7406 | OtherCommon Stock | 52,680 | $7.14 | $376,135.20 |
DisclosureSEC source: 0001842952-21-000027 · wf-form4a_163977590040895.xml · nonDerivative · entry 2 Lehr Martin A. · CIK 0001861989 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Martin Lehr 2000 Trust Disclosed balance after: 0 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.